Actos increases bladder cancer risk by 30.5%

This study was published in Diabetes Care 2012 Feb;35(2):278-80

Study title and author:
Pioglitazone and bladder cancer: a population-based study of Taiwanese.

Tseng CH.
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. ccktsh@ms6.hinet.net

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/22210574

The study investigated the association between pioglitazone (Actos) and bladder cancer. The study included 54,928 patients with type 2 diabetes who were followed for four years.

The study found those who had used Actos had a 30.5% increased risk of bladder cancer compared to those who had never used Actos.

For more information on the side-effects of Actos click here.